UK: The MHRA's Review Of The Human Medicines Regulations 2012

The UK's Medicines and Healthcare products Regulatory Agency has reviewed the implementation of the Human Medicines Regulations 2012. The Agency considers that, on balance, the Regulations represent a sound consolidation of complex medicines legislation. However, certain aspects of the Regulations require further work and this may result in additional guidance being issued by the MHRA (e.g., on cross-border prescriptions and wholesale dealing). Measures to encourage work-sharing between marketing authorisation holders in relation to pharmacovigilance obligations may also be adopted by the MHRA.

Background and summary

On 5 December 2017 the UK's Medicines and Healthcare products Regulatory Agency (MHRA) published a Post-implementation Review of the Human Medicines Regulations 2012 Review).

The Review assesses the effectiveness and impact of the Human Medicines Regulation 2012 (2012 Regulations), which were introduced in the UK with a view to implementing a series of EU directives and to consolidate UK medicines legislation. The Review also sets out recommendations about how to address shortcomings identified in the 2012 Regulations.

The obligation to carry out a review of the 2012 Regulations is set out in regulation 346. The focus of the review was on the principal changes introduced by the 2012 Regulations, comprising:

  • The impact of the consolidation of the previous UK legislation;
  • Implementation of Directive 2010/84/EU (Pharmacovigilance Directive);
  • EEA cross border prescriptions; and
  • The repeal of Section 10(7) of the Medicines Act 1968 (which provided an exemption for the requirement for a pharmacist in a registered pharmacy to hold a Wholesale Dealer's Licence if the pharmacy undertook wholesale trading in medicines in certain circumstances).

The 2012 Regulations are to be retained and, based on the Review, it seems that no major overhaul of these Regulations is to be expected. However, there are likely to be several pieces of guidance issued by the MHRA in the near future in relation to those aspects of the 2012 Regulations which have proved most controversial. It is hoped that these will provide welcome clarification. In addition, measures intended to ease the burden for manufacturers of generic medicinal products in relation to the maintenance and distribution of Risk Management Plans (RMPs) and Risk Minimisation Measures (RMMs) may be introduced shortly. The suggestion made by the MHRA in the Review is that work-sharing should be "encouraged" as between marketing authorisation (MA) holders, although some respondents to the consultation have suggested that work-sharing should be mandatory. It remains to be seen how, and in what form, the MHRA chooses to introduce any such new measures.


The issues identified above were the subject of a public consultation that ran from 15 June to 6 July 2017. Approximately 60 responses from a range of stakeholders were received. However, analysis of the consultation responses reveals that the majority of questions were skipped by responders. None of the consultation questions was individually addressed by more than 20 responders, and many questions were addressed by only a handful of responders. Owing to the low number of substantive responses to the consultation, it is arguable that the conclusions to be drawn therefrom are limited. Nevertheless, the Review relies significantly on the consultation to justify its analysis and recommendations regarding the 2012 Regulations.

Overall outcome and recommendations

The Review notes that, on balance, the 2012 Regulations represent a sound consolidation of fragmented and complex medicines legislation, presented in a simplified form to improve the coherence of the regulatory framework. However, the Review makes four recommendations. These are discussed in turn below.

  1. Obligations relating to RMPs and RMMs contained in the 2012 Regulations are a reflection of requirements contained in the Pharmacovigilance Directive. However, some consultation respondents point out that RMPs and RMMs are not always in the public domain. Even when these are accessible to applicants for generic (copy) products, documents submitted for assessment based on the originator's materials may have been assessed in an inconsistent manner, including by the MHRA. This has resulted in some MA holders having two or more RMPs for the same active substance. According to the responses received in the consultation, some MA holders for copy products consider the costs associated with RMM to be a barrier to market entry. The Review's Recommendation No. 1 is that, by March 2018, the MHRA is to have considered what more could be done to remove the potential barrier to market entry for such MA holders, arising from the current requirement to create and maintain RMPs and prepare and distribute RMMs. One option identified by the MHRA in the Review is to further encourage work sharing between MA holders.
  2. The consultation responses highlight several practical issues giving rise to increased workload for both prescribing healthcare professionals and pharmacists in connection with cross-border EEA prescriptions. Issues include inconsistent formatting of prescriptions from other EEA countries, prescriptions not written in English and prescriptions for medication not available in the UK. Verification of the prescription can also be time consuming. The Review's Recommendation No. 2 is that the MHRA shall review the guidance currently available to pharmacists and healthcare professionals on cross border prescriptions with a view to publishing by March 2018 a revised guidance to aid awareness and understanding.
  3. With regard to the repeal of Section 10(7) of the Medicines Act 1967, respondents to the consultation note that, although it may be reasonable to restrict wholesale dealing when it is being carried out commercially for profit, it has not been helpful to extend this restriction to the supply chain involving hospitals, pharmacies, and hospices. In the Review, the MHRA emphasises that there have been no reports of patients not receiving their medicines because of the repeal of Section 10(7). The Review's Recommendation No. 3 is that the MHRA shall consider concerns expressed in the consultation about the repeal of Section 10(7), and what further action might be appropriate (such as revised guidance). This will be completed by December 2018, to align with any new guidance on the safety feature element of the Falsified Medicines Directive coming into force in the UK.
  4. Lastly, the Review's Recommendation No. 4 provides that the MHRA shall (in consultation with NHS England and DH) consider an extension of prescribing responsibilities to particular groups of healthcare professionals operating in emergency care settings. The MHRA will also assess how best to publicise future amendments to the 2012 Regulations. This will be completed by March 2018 as part of the next set of amendments to the 2012 Regulations.


The big unknown hanging over the Review and its recommendations is the effect of the UK's decision to leave the EU, effective on 29 March 2019. For example, the consultation responses confirm that it is currently unclear what the implications of UK withdrawal are on cross-border EEA prescriptions. Unless there is immediate clarity on this issue, it may be difficult for the MHRA to provide anything more than short-term guidance by March 2018 (which is the deadline set for completion of Recommendation No. 2).

Depending on the extent to which UK law retains the EU pharmaceutical acquis following withdrawal, there may be opportunity to reassess those EU law-based requirements giving rise to concerns identified in connection with Recommendation Nos. 1, 2 and 3. For example, the UK's negotiation position in the lead up to finalisation of the Pharmacovigilance Directive was that RMPs should not be required for all MAs for generic products, but should instead depend on risk and the need for specific risk management. Following its withdrawal from the EU, it is possible that the UK could decide to reflect that position in domestic law. In so doing, the market access concerns of such manufacturers (discussed in connection with Recommendation No. 1) might be addressed, although it would be necessary to recognise the potential wider effects on market access of any decision which creates divergent pharmacovigilance requirements for the UK and EU respectively.

Lastly, it is arguable that the measure proposed in Recommendation No. 2 is unsuited to address the concerns identified in the consultation, which principally consist of practical issues associated with the processing of EEA generated prescriptions (e.g., inconsistent formatting, incomplete information, prescriptions for medicines not available in the UK). The MHRA plans to issue updated guidance to aid awareness and understanding of these requirements. However, there is no proposal to review and amend the rules themselves (to the extent such amendment would be consistent with EU law).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions